PRM35 Comparing Cost-Effectiveness Of Emerging Drugs In Advanced Cancer Without Hazard Ratios For Progression  by Wiecek, W & Karcher, H
A688  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  
associated with long-term mOCS use, and to quantify the cost and QALY burden 
of these events. Methods: A systematic review was undertaken to identify any 
studies reporting adverse event risk due to mOCS treatment. Seventy-two (72) stud-
ies were identified. The review focussed on eight disease outcomes representing 
the bulk of the mOCS cost and QALY burden: type II diabetes, myocardial infarc-
tion, glaucoma, cataract, ulcer, osteoporosis, infection, and stroke. A risk estimate 
for each adverse event was selected, based on the daily dose and mOCS exposure 
that best represented asthma-related mOCS use in Australian clinical practice. 
The excess risk of each complication in patients receiving mOCS, relative to those 
patients not receiving mOCS, was applied to the annual cost and QALY burden of 
each event in the Australian population. The cost and QALY burden attributable to 
mOCS was estimated on a per patient per year basis. Results: The expected annual 
cost of mOCS-related disease outcomes was estimated to be $598.32 per patient 
per year. Each patient treated with mOCS also suffers a QALY loss of 0.0367 per 
year of treatment. These effects are considered reversible once patients stop taking 
mOCS. ConClusions: mOCS are associated with a clear cost and QALY burden 
for patients with severe asthma which is likely underestimated by the approach 
adopted in this study. These results are likely to be useful for economic evaluations 
of new asthma interventions which replace or delay mOCS.
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objeCtives: To compare the cost-effectiveness via progression-free survival (PFS) for 
a new advanced cancer treatment (immuno-therapy A) against two active compara-
tors, both emerging drugs with publications reporting only their comparison against 
best supportive care (BSC) with progression-free survival curves, median survival and 
hazard ratios. Methods: PFS of therapy A compared to BSC could not be represented 
through a single hazard ratio (HR) estimates as progression hazards were obviously 
changing over the study course. Improvements in median PFS in all three studies 
were similar (2.5, 2.6, 2.6 months), while median PFS for BSC in three studies were: 5.0, 
6.7, 4.0 months. This highlighted the need for a meta-analysis to compare therapies. 
Instead of meta-analysing hazard ratios, the Ouwens method was applied to all six 
survival curves: (i) the curves were digitized and fitted to Weibull distributions, (ii) a 
fixed-effects model on shape and scale parameters was developed to deduce adjusted 
survival curves for the two comparators. Results: Two adjusted survival curves for 
comparator therapies were obtained and anchored to the control arm for therapy A. 
The areas under the adjusted PFS curves, with ratios 1.48 and 1.35 in favour of the new 
drug, were introduced in the cost-effectiveness model. ConClusions: The Ouwens 
method of meta-analysing progression-free survival curves was introduced into a 
cost-effectiveness model in advanced cancer. Meta-analysing not just the hazard ratio 
but a 2-parameter fit of the survival curves and adjusting survival curves accordingly 
enabled to build a cost effectiveness model in a situation where comparisons based 
on HR or on median survivals were not feasible.
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objeCtives: Health economic evaluations mostly present decision makers results 
without taking local constraints into account. This might influence the actual use-
fulness of studies and, more importantly, result in suboptimal decisions. Human 
resource constraints have been recently raised as a constraint that is of particular 
importance, especially in low and middle income countries. This review article aims 
to explore to what extent human resource constraints are taken into account in 
economic evaluations. Methods: We conducted systematic literature review via 7 
electronic databases and then consulted some experts for additional relevant articles. 
We searched for articles that investigate economic evaluations and mention human 
resource constraints. Subsequently, these articles were classified based on to what 
extent they addressed human resource constraints. We distinguished the categories 
‘ignoring’, ‘dealing’ and ‘relaxing’ human resource constraints. Furthermore, we clas-
sified studies into modelling studies and studies based on primary data. Results: 
We found 200 articles, approximately. The findings show that 164 articles ignore the 
constraints, accounting for 88 and 76 articles of primary data use and modelling use, 
respectively. Only 32 articles deal with or relax the constraints. Of these articles, 27 
articles focus on the task shifting and the rest of them were distributed to the cat-
egories of dealing and relaxing, almost equally between modelling use and primary 
data use. ConClusions: Many cost effectiveness studies were conducted in settings 
in which human resource constraints are important. Although this is acknowledged, 
human resource constraints are often ignored in health economic evaluations. This 
practice results in biased estimates of the cost-effectiveness of interventions and 
misinforms decision makers. Guidance on how to properly deal with human resource 
constraints in cost-effectiveness analyses is needed.
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objeCtives: Constructing a Markov model can be challenging as available data 
can be limited. In hepatitis C, more complex models that includes F0, F1, F2, F3 
and F4 fibrosis states are required by HTA agencies. However transition probabili-
ties (TP) can only be available for non-cirrhotic to cirrhotic states (simple model). 
Estimating separate TP for Fn to Fn+1 (Fn,n+1) can be challenging as Markov models 
are non-linear. The objective of this study was to estimate Fn,n+1 TP from a single 
non-cirrhotic (F0F3) to cirrhotic (F4) TP. Methods: Results in markov models are 
driven by sum of cycles spent in each state. Thus, the method was built to produce 
per minute for basic surgical procedure, excluding physician costs) were used to 
estimate potential savings. Results: There were a total of 239 cases: Cf= 118 and 
Rv= 121 patients. There were no significant differences between Cf and Rv patients 
in mean age, BMI, smoking status, diabetes, and prior radiation. Mean volume of 
fat harvested (499.5 vs 122.9 ml) and injected (178.9 vs 78.0 mL) were significantly 
higher (p< 0.0001) in the Rv group compared to the Cf group, respectively. Mean time 
to complete fat grafting was significantly shorter in the Rv group compared to the 
Cf group (35.3 vs 89.8 minutes, respectively; p< 0.0001). Mean OR costs with Rv were 
estimated to be $529-$706 vs $1347-$1796 with Cf. After taking into consideration 
the cost of Rv ($470), the potential net savings in mean OR costs were $347-$620 per 
case. ConClusions: The Rv fat processing system decreased operative time, which 
translated into a potential cost savings, and allowed for a larger volume of fat to be 
processed for injection compared to standard centrifugation.
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objeCtives: The NICE methods for technology appraisal require systematic litera-
ture reviews across clinical, cost-effectiveness, cost and resource use and health 
state utility values. These searches are a key component of a manufacturer sub-
mission. Whilst differences in population terms are expected across appraisals, 
this study reviewed search strategies submitted in three recent NICE appraisals 
to assess whether search terms used for methodological filters were consistent. 
The choice of databases searched were also reviewed. Methods: NICE technology 
appraisals were reviewed in reverse chronological order. Manufacturer submissions 
were searched to identify those that reported the search terms used. In order to 
keep the search manageable, a target of three papers was set in the first instance. 
Search terms for the following methodological filters were extracted: quality of 
life, cost and resource use, and cost-effectiveness. Results were compared quali-
tatively to assess the consistencies across search terms. Also extracted were the 
databases searched, presentation of search protocols and any Evidence Review 
Group (ERG) comments. Results: Search terms used for the methodological fil-
ters varied across submissions and similarly the databases searched differed. This 
was noted for all searches, with the comprehensiveness of searches differing across 
the three appraisals. In consideration of the presentation of search protocols, there 
was further variation resulting in lack of transparency. A common approach was 
to run a single search strategy for the cost-effectiveness and cost and resource 
use reviews. ConClusions: From this initial review there appears to be a lack of 
consistency in search terms included and databases searched in NICE technology 
appraisals. Whilst generic search filters are available there appears to be a need to 
drive awareness and application of these search terms. The implication for technol-
ogy appraisals is decision making based on non-optimized evidence bases.
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objeCtives: To review the content of existing resource-use measures with a view 
to conducting a Delphi survey to identify core items that should be included in any 
UK trial-based economic evaluation. bACkgRound: Resource-use measurement 
by patient recall in economic evaluations alongside clinical trials is currently char-
acterised by inconsistency and a lack of validation. A fully validated standardised 
resource-use measure could potentially increase data quality, improve compara-
bility between cost-effectiveness analyses and reduce research burden on health 
economists. Methods: A single version of each instrument designed for use in 
a UK-based study was identified from the Database of Instruments for Resource-
Use Measurement (www.dirum.org). Section headings (‘domains’) and questions 
(‘items’) were extracted verbatim according to a predefined schema. Information 
on the recall period, level of detail, use of skip logic (i.e. a yes/no question designed 
to guide responders past irrelevant questions) and scope (disease-specific or total 
resource use) was also extracted. Items were scrutinised for overlap. Results: In 
excess of 2000 items were extracted from 59 instruments. The range of structures 
used to collect data was extremely wide, and varying levels of information were 
requested about similar items (for example, the number of hospital stays or the 
number of nights spent in hospital). Recall periods varied substantially (sometimes 
within an instrument), and total resource use was more commonly requested than 
disease-specific resource use. Skip logic was employed in over half the instruments 
reviewed. The original items were reduced to a list of 350 following preliminary 
scrutiny for overlap, and further reduced to approximately 60 key items for future 
inclusion in a Delphi survey of health economists.PReliMinARY ConClusions: 
There is substantial variation in the methods used to assess resource use in clini-
cal trials. Further work is in progress to prepare and administer the Delphi survey.
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objeCtives: Maintenance oral corticosteroids (mOCS) are used in the treatment 
of severe asthma where patients have exhausted other available options with-
out achieving acceptable control of their symptoms. However, long-term mOCS 
is associated with the development of a number of serious adverse events. These 
complications cause considerable healthcare costs and quality-adjusted life year 
(QALY) losses. The aim of this study was to establish the excess risk of complications 
